NO20044138L - Krystallinsk polymorf form av irinotekanhydroklorid - Google Patents
Krystallinsk polymorf form av irinotekanhydrokloridInfo
- Publication number
- NO20044138L NO20044138L NO20044138A NO20044138A NO20044138L NO 20044138 L NO20044138 L NO 20044138L NO 20044138 A NO20044138 A NO 20044138A NO 20044138 A NO20044138 A NO 20044138A NO 20044138 L NO20044138 L NO 20044138L
- Authority
- NO
- Norway
- Prior art keywords
- polymorphic form
- irinotecan hydrochloride
- crystalline polymorphic
- crystalline
- irinotecan
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36068402P | 2002-03-01 | 2002-03-01 | |
| PCT/EP2003/001948 WO2003074527A1 (fr) | 2002-03-01 | 2003-02-26 | Forme polymorphique cristalline de chlorhydrate d'irinotecan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20044138L true NO20044138L (no) | 2004-11-29 |
Family
ID=27789001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20044138A NO20044138L (no) | 2002-03-01 | 2004-09-29 | Krystallinsk polymorf form av irinotekanhydroklorid |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1487840B1 (fr) |
| JP (1) | JP2005525367A (fr) |
| KR (1) | KR20040091083A (fr) |
| CN (1) | CN1276923C (fr) |
| AR (1) | AR038618A1 (fr) |
| AT (1) | ATE364610T1 (fr) |
| AU (1) | AU2003215594A1 (fr) |
| BR (1) | BR0308133A (fr) |
| CA (1) | CA2477926A1 (fr) |
| DE (1) | DE60314378T2 (fr) |
| DK (1) | DK1487840T3 (fr) |
| ES (1) | ES2287495T3 (fr) |
| HK (1) | HK1075044A1 (fr) |
| IL (1) | IL163820A0 (fr) |
| MX (1) | MXPA04008484A (fr) |
| NO (1) | NO20044138L (fr) |
| NZ (1) | NZ534999A (fr) |
| PE (1) | PE20030923A1 (fr) |
| PL (1) | PL372318A1 (fr) |
| PT (1) | PT1487840E (fr) |
| RU (1) | RU2300535C2 (fr) |
| TW (1) | TWI270374B (fr) |
| WO (1) | WO2003074527A1 (fr) |
| ZA (1) | ZA200406927B (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004076460A1 (fr) * | 2003-02-25 | 2004-09-10 | Kabushiki Kaisha Yakult Honsha | Procede de preparation d'un polymorphisme de chlorhydrate d'irinotecane |
| ES2245891B1 (es) * | 2004-07-09 | 2006-11-16 | Clinmet S.L. | "metodo para la obtencion de un excipiente universal para la administracion oral de principios activos farmaceuticos y composiciones de excipientes resultantes del metodo". |
| AU2005318227B2 (en) | 2004-12-21 | 2011-08-18 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Stereoselective process and crystalline forms of a camptothecin |
| DE602006009901D1 (de) | 2005-02-07 | 2009-12-03 | Fermion Oy | Verfahren zur herstellung von 7-ethyl-10-hydroxycamptothecin |
| CA2591074C (fr) | 2005-02-08 | 2015-01-20 | Fermion Oy | Procede d'elaboration |
| JP5133703B2 (ja) | 2005-02-08 | 2013-01-30 | フェルミオン オサケ ユキチュア | ［１，４’］ビピペリジニル−１’−カルボニルクロリドまたはその塩酸塩の製造方法 |
| EP1951235B1 (fr) * | 2005-09-20 | 2010-03-10 | Scinopharm Singapore Pte, Ltd. | Nouvelles formes cristallines de chlorhydrate d'irinotecan |
| CN101318964B (zh) * | 2007-06-07 | 2010-12-15 | 上海迪赛诺医药发展有限公司 | 盐酸伊立替康新晶型及其制备方法 |
| FR2918279B1 (fr) * | 2007-07-05 | 2010-10-22 | Aventis Pharma Sa | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan |
| IT1391757B1 (it) * | 2008-11-11 | 2012-01-27 | Antibioticos Spa | Irinotecan cloridrato cristallino e metodi per la sua preparazione |
| CN101659667B (zh) * | 2009-09-07 | 2011-11-02 | 重庆泰濠制药有限公司 | 一种盐酸伊立替康的纯化方法 |
| US8546573B2 (en) | 2009-11-18 | 2013-10-01 | Cadila Healthcare Limited | Process for the preparation of 7-ethyl-10-[4-(1-piperidino)-1-piperdino] carbonyloxy-camptothecin hydrochloride trihydrate |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| CN102866126B (zh) * | 2011-07-05 | 2016-03-23 | 重庆华邦制药有限公司 | 一种定量测定化合物中晶型比例的方法 |
| CN102311443B (zh) * | 2011-08-24 | 2014-07-16 | 上海北卡医药技术有限公司 | 盐酸伊立替康的新晶型及其制备方法 |
| RU2529831C2 (ru) * | 2012-11-30 | 2014-09-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Российский университет дружбы народов" (РУДН) | Способ лечения рака толстой кишки |
| MA40354A (fr) | 2014-07-18 | 2017-05-24 | Sanofi Sa | Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer |
| KR102293907B1 (ko) * | 2015-06-30 | 2021-08-26 | 한미약품 주식회사 | 이리노테칸 함유 경구용 고형제제 및 그 제조방법 |
| KR102066402B1 (ko) * | 2017-12-22 | 2020-01-15 | 대화제약 주식회사 | 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물 |
| US10919905B2 (en) * | 2019-05-16 | 2021-02-16 | Scinopharm Taiwan, Ltd. | Polymorphism for irinotecan free base |
-
2003
- 2003-02-26 BR BR0308133-8A patent/BR0308133A/pt not_active IP Right Cessation
- 2003-02-26 WO PCT/EP2003/001948 patent/WO2003074527A1/fr active IP Right Grant
- 2003-02-26 DK DK03743335T patent/DK1487840T3/da active
- 2003-02-26 ES ES03743335T patent/ES2287495T3/es not_active Expired - Lifetime
- 2003-02-26 MX MXPA04008484A patent/MXPA04008484A/es not_active Application Discontinuation
- 2003-02-26 KR KR10-2004-7013621A patent/KR20040091083A/ko not_active Application Discontinuation
- 2003-02-26 CN CNB038072726A patent/CN1276923C/zh not_active Expired - Fee Related
- 2003-02-26 PT PT03743335T patent/PT1487840E/pt unknown
- 2003-02-26 RU RU2004129307/04A patent/RU2300535C2/ru not_active IP Right Cessation
- 2003-02-26 JP JP2003572995A patent/JP2005525367A/ja not_active Withdrawn
- 2003-02-26 EP EP03743335A patent/EP1487840B1/fr not_active Expired - Lifetime
- 2003-02-26 AU AU2003215594A patent/AU2003215594A1/en not_active Abandoned
- 2003-02-26 IL IL16382003A patent/IL163820A0/xx unknown
- 2003-02-26 NZ NZ534999A patent/NZ534999A/en unknown
- 2003-02-26 PL PL03372318A patent/PL372318A1/xx not_active Application Discontinuation
- 2003-02-26 CA CA002477926A patent/CA2477926A1/fr not_active Abandoned
- 2003-02-26 AT AT03743335T patent/ATE364610T1/de not_active IP Right Cessation
- 2003-02-26 DE DE60314378T patent/DE60314378T2/de not_active Expired - Fee Related
- 2003-02-27 TW TW092104194A patent/TWI270374B/zh not_active IP Right Cessation
- 2003-02-28 PE PE2003000196A patent/PE20030923A1/es not_active Application Discontinuation
- 2003-02-28 AR ARP030100656A patent/AR038618A1/es unknown
-
2004
- 2004-08-31 ZA ZA200406927A patent/ZA200406927B/en unknown
- 2004-09-29 NO NO20044138A patent/NO20044138L/no not_active Application Discontinuation
-
2005
- 2005-08-22 HK HK05107303A patent/HK1075044A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2300535C2 (ru) | 2007-06-10 |
| TW200303753A (en) | 2003-09-16 |
| CN1276923C (zh) | 2006-09-27 |
| PL372318A1 (en) | 2005-07-11 |
| PT1487840E (pt) | 2007-09-11 |
| EP1487840A1 (fr) | 2004-12-22 |
| ES2287495T3 (es) | 2007-12-16 |
| WO2003074527A1 (fr) | 2003-09-12 |
| CN1642958A (zh) | 2005-07-20 |
| PE20030923A1 (es) | 2003-10-29 |
| RU2004129307A (ru) | 2005-04-10 |
| AU2003215594A1 (en) | 2003-09-16 |
| ATE364610T1 (de) | 2007-07-15 |
| KR20040091083A (ko) | 2004-10-27 |
| BR0308133A (pt) | 2005-01-04 |
| ZA200406927B (en) | 2006-06-28 |
| JP2005525367A (ja) | 2005-08-25 |
| HK1075044A1 (en) | 2005-12-02 |
| DE60314378T2 (de) | 2008-02-28 |
| AR038618A1 (es) | 2005-01-19 |
| DE60314378D1 (en) | 2007-07-26 |
| MXPA04008484A (es) | 2004-12-06 |
| EP1487840B1 (fr) | 2007-06-13 |
| DK1487840T3 (da) | 2007-07-16 |
| CA2477926A1 (fr) | 2003-09-12 |
| IL163820A0 (en) | 2005-12-18 |
| TWI270374B (en) | 2007-01-11 |
| NZ534999A (en) | 2007-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1075044A1 (en) | Crystalline polymorphic form of irinotecan hydrochloride | |
| HK1093483A1 (en) | Polymorphic form of n- | |
| IL172006A0 (en) | Novel crystalline forms of valacyclovir hydrochloride | |
| EP1773339A4 (fr) | Forme cristalline d'hydrochlorure de donepezil | |
| IL175514A0 (en) | Polymorphic form b2 of ziprasidone base | |
| IL176141A0 (en) | Crystalline forms of valacyclovir hydrochloride | |
| IL174213A0 (en) | A polymorphic form of 3-phenylsulfonyl-8-piperazin-1-yl-quinoline | |
| NO20040266L (no) | Nye krystallinske polymorfe former av lerkanidipinhydroklorid og fremgangsmate for fremstilling derav | |
| IL192360A0 (en) | Crystalline polymorphic forms of olopatadine hydrochloride and processes for their preparation | |
| IL170350A (en) | Method for preparing polymorphism of irinotecan hydrochloride | |
| AU2003245029A1 (en) | Novel crystalline forms of donepezil hydrochloride | |
| AU2003245027A1 (en) | Novel crystalline forms of ziprasidone hydrochloride | |
| AU2003232719A1 (en) | Novel crystalline forms of valacyclovir hydrochloride | |
| IL166592A0 (en) | Novel crystalline forms of gatifloxacin | |
| IL165115A0 (en) | Novel crystalline forms of gatifloxacin | |
| NO20055097D0 (no) | Krystallinske N-formyl-hydroksylaminforbindelser | |
| AU2003289995A1 (en) | Anhydrous crystalline form of valacyclovir hydrochloride | |
| ITMI20042437A1 (it) | Forma cristallina di rabeprazolo sodico | |
| IL174969A0 (en) | Crystalline forms of (+)-and (-) erythro-mefloquine hydrochloride | |
| PT1656358E (pt) | Polimorfo est?vel de mesilato de bifeprunox | |
| AU2003250086A1 (en) | Crystalline polymorphic and amorphous forms of benazepril hydrochloride | |
| SI1487840T1 (sl) | Kristalinična polimorfna oblika irinotekan hidroklorida | |
| IL165690A0 (en) | Novel crystalline forms of gatifloxacin | |
| PL1626051T3 (pl) | Kryształy solwatu pochodnej kwasu chinolinokarboksylowego | |
| ITMI20020488A1 (it) | Forma cristallina di venlafaxina cloridrato |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |